Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

Diagnostic Excellence

Yang and colleagues (2021) define diagnostic excellence as “an optimal process to attain an accurate and precise explanation about a patient’s condition. An optimal process would be timely, cost-effective, convenient, and understandable to the patient. An accurate and precise diagnosis gains clinical value insofar as it leads to better choices in treatment.” The American Urological Association (AUA) highlighted “enhancing diagnostic excellence” as a top priority in its National Quality Agenda and Strategies for Urologic Practice, emphasizing its importance in improving urologic health and urologic health care.

PSA Screening: Resources for Urologists, Primary Care Providers, and Patients

The Prostate-Specific Antigen (PSA) test is the tool most commonly used by both primary care providers (PCPs) and urologists to screen for prostate cancer. In its 2023 Early Detection of Prostate Cancer guideline, the AUA provides age- and risk-based recommendations for PSA screening and encourages shared decision-making regarding when to initiate, resume, and discontinue screening. Appropriate use of PSA screening is a key component of diagnostic excellence for urology. 

In 2023, the AUA received a grant from the Council of Medical Specialty Societies to promote diagnostic excellence and health equity in urology care. The objectives of this project were to increase awareness of general principles of diagnostic excellence and address the diagnostic challenges faced by urologists, PCPs, and Black men related to the early detection of prostate cancer. The AUA believes that the resources developed as part of this project will be valuable for urologists, PCPs, and patients in enhancing the early detection of prostate cancer through PSA screening.

Development of the following resources was funded by the Gordon and Betty Moore Foundation and the John A. Hartford Foundation through a grant program administered by the Council of Medical Specialty Societies. 

advertisement

advertisement